Epitalon (Epithalon)

Typical use cases

Dosing guidelines

Titration

No formal titration scheme is established; protocols are generally described as fixed-dose courses (e.g., 10-20 consecutive days) repeated cyclically rather than gradually escalated

Reconstitution

Lyophilized powder reconstituted with bacteriostatic water (e.g., 2 mL per 10 mg vial yields ~5 mg/mL) for subcutaneous use; swirl gently, do not shake

Injection sites

Subcutaneous injection (commonly abdomen or other subcutaneous sites); intranasal and oral/sublingual forms are also described in some research and community use

Storage & handling

Store lyophilized powder refrigerated (2-8 C) or frozen for long-term storage, protected from light; once reconstituted, keep refrigerated and use within a few weeks

Side effects

• Injection-site reaction (redness, swelling, irritation) Mild · Common
• Drowsiness or changes in sleep pattern Mild · Uncommon
• Headache Mild · Uncommon
• Theoretical concern: telomerase/ALT activation and unknown long-term cancer-promotion risk Severe · Rare
• Allergic / hypersensitivity reaction Moderate · Rare

Research summary

Epitalon is the synthetic tetrapeptide Ala-Glu-Asp-Gly (AEDG), identified as the putative active fragment of the bovine pineal extract epithalamin and developed by Vladimir Khavinson's group in Russia. The strongest mechanistic data are preclinical: in human cell culture it has been reported to upregulate hTERT expression and telomerase activity, lengthen telomeres, and let fibroblasts divide past the Hayflick limit; in rodents and Drosophila various studies report reduced spontaneous tumor incidence, increased antioxidant enzyme activity, restored melatonin rhythms, and modestly extended lifespan. Proposed mechanisms include telomerase induction, modulation of circadian/clock-gene expression, restoration of pineal melatonin output, and direct DNA/epigenetic binding, but the complete mechanism remains unclear. Most positive findings historically came from a single research lineage, but a 2025 independent study from Brunel University London replicated dose-dependent telomere elongation in normal human cell lines via telomerase upregulation, and reported telomere extension in cancer cell lines via alternative lengthening of telomeres (ALT) — a result that underscores the unresolved long-term cancer-safety question. Human evidence is limited and largely from the original Russian group: the most cited is a long-term controlled study of elderly cardiac patients given the related preparation epithalamin in courses over 3 years, reporting lower mortality at 15-year follow-up, plus small trials in retinitis pigmentosa and circadian/melatonin endpoints. Major limitations are that most human data come from one group, trials are small and often unblinded, frequently use epithalamin (the extract) rather than pure epitalon, and a 2025 review notes that comprehensive toxicity, genotoxicity, and carcinogenicity data remain missing. Overall the compound is biologically interesting and reportedly well-tolerated in the short term, but the human longevity claims remain preliminary and not validated by large, independent clinical trials.

Key references

• https://pmc.ncbi.nlm.nih.gov/articles/PMC11943447/
• https://pubchem.ncbi.nlm.nih.gov/compound/Epitalon
• https://pubmed.ncbi.nlm.nih.gov/12937682/
• https://pubmed.ncbi.nlm.nih.gov/22451889/
• https://link.springer.com/article/10.1007/s10522-025-10315-x

Related compounds